U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.